ERBB2 and breast carcinoma: As mentioned in the previous part, the immunogenicity of breast cancer varies among multiple molecular variants, with TNBC and HER2+ tumors being more immunogenic, while luminal A and luminal B subtypes are less immunogenic.119 Since breast cancer is a highly heterogeneous disorder, it is not surprising that the subtype changes metastasis or under the pressure of therapies.122 Neoadjuvant chemotherapy can probably change ER and PR expression and status.